LUCD dividend history
Lucid Diagnostics Inc. (LUCD) dividend declarations and ex-dividend dates - real-time wire coverage of every payout disclosure.
Which date decides who gets paid? Dividend dates explained
Recent dividend items
- Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard® and Closes $15 Million FinancingLucid is now submitting Medicare claims and receiving payments at EsoGuard's established Clinical Laboratory Fee Schedule rateSeries C Preferred Stock private placement with existing long-term shareholders strengthens Lucid's balance sheet, extends its cash runway, and supports near-term commercial accelerationNEW YORK, Oct. 22, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it has begun receiving payments from Medicare for its EsoGuard® Esophageal DNA Test. The Company also closed a $15.0 million private placement on Octob
- PAVmed Provides Additional Details for Upcoming Stock Dividend to ShareholdersPAVmed shareholders as of January 15, 2024 will participate in distribution of approximately 3.3 million shares of Lucid common stock NEW YORK, Dec. 11, 2023 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM, PAVMZ))) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors today provided additional details on the previously announced dividend of common stock of its majority-owned subsidiary, Lucid Diagnostics Inc. (NASDAQ:LUCD) for PAVmed shareholders. On December 4, 2023, the Compa
- PAVmed Announces Dividend of Lucid Diagnostics Common Stock and Reverse Stock SplitPAVmed shareholders as of January 15, 2024 will participate in distribution of approximately 3.3 million shares of Lucid common stock 1-for-15 reverse stock split to be effective as of market open on December 7, 2023 NEW YORK, Dec. 4, 2023 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM, PAVMZ))) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors today announced a dividend of approximately 3.3 million shares of common stock of its majority-owned subsidiary, Lucid Diagnostics Inc. (NASDAQ:LUCD), which equals the number of shares PAVmed will receive in the contemporaneous partial settlement